Assess whether a top customer is actually sticky (9561c1)

Situation

In a cross-border deal with earnout-heavy structure, regulatory-approval critical-path calendar is the evidence after add-backs that are just delayed opex. Customer-contract risk reviewer has to pick Proceed or Reprice for this M&A Due Diligence Earnings and Revenue Quality close using regulatory-approval critical-path calendar.

Decision

Customer-contract risk reviewer in a cross-border deal with earnout-heavy structure must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after add-backs that are just delayed opex.

Hypotheses to test

• Regulatory-approval critical-path calendar reads as Proceed once add-backs that are just delayed opex is lined up to the same M&A Due Diligence population.
• Regulatory-approval critical-path calendar is closer to Reprice after add-backs that are just delayed opex; Proceed would over-claim this Earnings and Revenue Quality extract.
• Walk is still live in regulatory-approval critical-path calendar for customer-contract risk reviewer in a cross-border deal with earnout-heavy structure.
• Regulatory-approval critical-path calendar is missing the fact customer-contract risk reviewer needs after add-backs that are just delayed opex; stop this M&A Due Diligence close.

Analysis required

• Test whether add-backs that are just delayed opex is a diligence gap, a price chip, or a walk-away.
• Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar.
• Map reps, earnout mechanics, and integration risk a cross-border deal with earnout-heavy structure would inherit.
• For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against add-backs that are just delayed opex and write the one fact that would move a top customer is actually sticky for customer-contract risk reviewer.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after add-backs that are just delayed opex). If regulatory-approval critical-path calendar cannot force a M&A Due Diligence label under Earnings and Revenue Quality, stop. Do not invent pages a cross-border deal with earnout-heavy structure does not have.